BRPA Share Price | NRX Pharmaceuticals, Inc. Stock Analysis & Recommendation

Q: Is NRX Pharmaceuticals, Inc. technically bullish or bearish?

As of 7 July 2025, the technical trend for NRX Pharmaceuticals, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is mildly bullish, indicating mixed signals. The Bollinger Bands are bullish for both weekly and monthly time frames, and the daily moving averages are bullish, supporting a positive short-term outlook. However, the KST and OBV show mild bearishness on the weekly, with Dow Theory indicating no trend. In terms of performance, NRX Pharmaceuticals has outperformed the S&P 500 over the past week (3.47% vs. 1.05%), month (7.97% vs. 2.33%), year-to-date (35.45% vs. 12.22%), and year (83.95% vs. 17.14%), but has significantly underperformed over the 3-year and 5-year periods. Overall, the current technical stance is mildly bullish, driven by the daily moving averages and Bollinger Bands, despite some bearish indicators on the weekly timeframe.

Q: How big is NRX Pharmaceuticals, Inc.?

Market Cap: As of Jun 18, NRX Pharmaceuticals, Inc. has a market capitalization of 57.75 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, NRX Pharmaceuticals reported net sales of 0.00 million and a net profit of -24.11 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of -23.22 million and total assets of 3.65 million.

Q: What does NRX Pharmaceuticals, Inc. do?

Overview:NRX Pharmaceuticals, Inc. is a blank check company in the Pharmaceuticals & Biotechnology industry, formed for the purpose of engaging in business combinations.Financial Snapshot:Most recent Net Profit: -6 Million (Quarterly Results - Mar 2025)Market cap: USD 57.75 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making)Industry P/E: NADividend Yield: 0.00%Debt Equity: -0.11Return on Equity: 72.66%Price to Book: -2.30Contact Details:Address: 2645 N Federal Hwy Ste 230, DELRAY BEACH FL: 33483-6111Tel: 1 310 7342300Fax: 1 302 6555049Website: https://www.bigrockpartners.com/spac/spac_aboutus.html

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

152.93 k

Shareholding (Mar 2026)

FII

1.28%

Held by 8 FIIs

DII

98.71%

Held by 9 DIIs

Promoter

0.00%

Is NRX Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of July 7, 2025, NRX Pharmaceuticals shows a mildly bullish trend with positive short-term indicators, despite mixed signals from MACD and some bearishness on the weekly timeframe, while outperforming the S&P 500 in various timeframes but underperforming over the long term.

View full answer

How big is NRX Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, NRX Pharmaceuticals, Inc. has a market capitalization of 57.75 million, with net sales of 0.00 million and a net profit of -24.11 million over the last four quarters. The company reported shareholder's funds of -23.22 million and total assets of 3.65 million as of Dec 24.

View full answer

What does NRX Pharmaceuticals, Inc. do?

22-Jun-2025

NRX Pharmaceuticals, Inc. is a blank check company in the Pharmaceuticals & Biotechnology sector focused on business combinations. It has a market cap of $57.75 million and reported a net profit loss of $6 million as of March 2025.

View full answer

Compare NRX Pharmaceuticals, Inc. with Similar Stocks

NLS Pharmaceutics Ltd.Cumberland Pharmaceuticals, Inc.MyMD Pharmaceuticals, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Net Sales has grown by an annual rate of 17.40% and Operating profit at -270.48% over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -16.34

Flat results in Mar 26

Risky -

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 72 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.47

Return on Equity

72.25%

Price to Book

-4.54

Revenue and Profits:

Net Sales:

1 Million

(Quarterly Results - Mar 2026)

Net Profit:

-1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

112.43%

6 Months

57.32%

1 Year

21.29%

2 Years

41.89%

3 Years

649.0%

4 Years

-36.42%

5 Years

-97.18%

NRX Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

17.40%

EBIT Growth (5y)

-270.48%

EBIT to Interest (avg)

-16.34

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.11

Sales to Capital Employed (avg)

-0.05

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

44.73%

ROCE (avg)

ROE (avg)

0.23%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-4.54

EV to EBIT

-4.01

EV to EBITDA

-4.05

EV to Capital Employed

-2.77

EV to Sales

53.01

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

Mildly Bullish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 6 Schemes (8.26%)

Foreign Institutions

Held by 8 Foreign Institutions (1.28%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 74.55% vs 15.38% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.60",
          "val2": "-3.70",
          "chgp": "-24.32%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "3.50",
          "val2": "-1.80",
          "chgp": "294.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.40",
          "val2": "-5.50",
          "chgp": "74.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-4,445.70%",
          "val2": "0.00%",
          "chgp": "-444.57%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -13.94% vs 16.61% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-16.00",
          "val2": "-19.70",
          "chgp": "18.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.70",
          "val2": "1.10",
          "chgp": "-36.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-15.80",
          "val2": "-4.40",
          "chgp": "-259.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-28.60",
          "val2": "-25.10",
          "chgp": "-13.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-13,214.70%",
          "val2": "0.00%",
          "chgp": "-1,321.47%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY

Mar'26

Mar'25

Change(%)

Net Sales

1.10

0.00

Operating Profit (PBDIT) excl Other Income

-4.60

-3.70

-24.32%

Interest

0.20

0.00

Exceptional Items

3.50

-1.80

294.44%

Consolidate Net Profit

-1.40

-5.50

74.55%

Operating Profit Margin (Excl OI)

-4,445.70%

0.00%

-444.57%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Mar 2025

Consolidated Net Profit

YoY Growth in quarter ended Mar 2026 is 74.55% vs 15.38% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

1.20

0.00

Operating Profit (PBDIT) excl Other Income

-16.00

-19.70

18.78%

Interest

0.70

1.10

-36.36%

Exceptional Items

-15.80

-4.40

-259.09%

Consolidate Net Profit

-28.60

-25.10

-13.94%

Operating Profit Margin (Excl OI)

-13,214.70%

0.00%

-1,321.47%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -13.94% vs 16.61% in Dec 2024

All Annual Results

Company CV

About NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

Big Rock Partners Acquisition Corp. is a blank check company. The Company is formed for the purpose of entering into a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities. The Company is not limited to a particular industry or geographic region for purposes of consummating a business combination. The Company has not commenced any business operation and has not generated any revenue.

Company Coordinates

Company Details

2645 N Federal Hwy Ste 230 , DELRAY BEACH FL : 33483-6111

Tel: 1 310 7342300

https://www.bigrockpartners.com/spac/spac_aboutus.html

Registrar Details